Flaviano Giorgini

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1380542/publications.pdf

Version: 2024-02-01

64 papers	8,374 citations	147801 31 h-index	102487 66 g-index
69 all docs	69 docs citations	69 times ranked	17811 citing authors

#	Article	IF	Citations
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
2	Kynurenine 3-Monooxygenase Inhibition in Blood Ameliorates Neurodegeneration. Cell, 2011, 145, 863-874.	28.9	435
3	A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease. Nature Genetics, 2005, 37, 526-531.	21.4	323
4	The Kynurenine Pathway Modulates Neurodegeneration in a Drosophila Model of Huntington's Disease. Current Biology, 2011, 21, 961-966.	3.9	231
5	The kynurenine pathway and neurodegenerative disease. Seminars in Cell and Developmental Biology, 2015, 40, 134-141.	5.0	223
6	Glycation potentiates Î±-synuclein-associated neurodegeneration in synucleinopathies. Brain, 2017, 140, 1399-1419.	7.6	153
7	A network of protein interactions determines polyglutamine toxicity. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 11051-11056.	7.1	141
8	Structural basis of kynurenine 3-monooxygenase inhibition. Nature, 2013, 496, 382-385.	27.8	124
9	Glutathione peroxidase activity is neuroprotective in models of Huntington's disease. Nature Genetics, 2013, 45, 1249-1254.	21.4	117
10	Tryptophan-2,3-dioxygenase (TDO) inhibition ameliorates neurodegeneration by modulation of kynurenine pathway metabolites. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 5435-5440.	7.1	117
11	DJ-1 in Parkinsonâ€™s Disease: Clinical Insights and Therapeutic Perspectives. Journal of Clinical Medicine, 2019, 8, 1377.	2.4	101
12	A Drosophila RNAi collection is subject to dominant phenotypic effects. Nature Methods, 2014, 11, 222-223.	19.0	100
13	Targeted Deletion of Kynurenine 3-Monooxygenase in Mice. Journal of Biological Chemistry, 2013, 288, 36554-36566.	3.4	99
14	Rab11 modulates Î±-synuclein-mediated defects in synaptic transmission and behaviour. Human Molecular Genetics, 2015, 24, 1077-1091.	2.9	94
15	Histone Deacetylase Inhibition Modulates Kynurenine Pathway Activation in Yeast, Microglia, and Mice Expressing a Mutant Huntingtin Fragment. Journal of Biological Chemistry, 2008, 283, 7390-7400.	3.4	86
16	Î±-Synuclein interacts with the switch region of Rab8a in a Ser129 phosphorylation-dependent manner. Neurobiology of Disease, 2014, 70, 149-161.	4.4	84
17	The small GTPase Rab11 co-localizes with Â-synuclein in intracellular inclusions and modulates its aggregation, secretion and toxicity. Human Molecular Genetics, 2014, 23, 6732-6745.	2.9	73
18	Targeting Kynurenine 3-Monooxygenase (KMO): Implications for Therapy in Huntingtons Disease. CNS and Neurological Disorders - Drug Targets, 2010, 9, 791-800.	1.4	71

#	Article	IF	Citations
19	Rab11 rescues synaptic dysfunction and behavioural deficits in a Drosophila model of Huntington's disease. Human Molecular Genetics, 2012, 21, 2912-2922.	2.9	68
20	shRNA-Based Screen Identifies Endocytic Recycling Pathway Components That Act as Genetic Modifiers of Alpha-Synuclein Aggregation, Secretion and Toxicity. PLoS Genetics, 2016, 12, e1005995.	3.5	68
21	Adaptive and Behavioral Changes in Kynurenine 3-Monooxygenase Knockout Mice: Relevance to Psychotic Disorders. Biological Psychiatry, 2017, 82, 756-765.	1.3	57
22	Functional Gene Expression Profiling in Yeast Implicates Translational Dysfunction in Mutant Huntingtin Toxicity. Journal of Biological Chemistry, 2011, 286, 410-419.	3.4	51
23	Modeling Huntington disease in yeast: Perspectives and future directions. Prion, 2011, 5, 269-276.	1.8	49
24	Yeast as a drug discovery platform in Huntington's and Parkinson's diseases. Biotechnology Journal, 2006, 1, 258-269.	3.5	48
25	Deubiquitinase Usp12 functions noncatalytically to induce autophagy and confer neuroprotection in models of Huntingtonâ€™s disease. Nature Communications, 2018, 9, 3191.	12.8	47
26	Yeast DJ-1 superfamily members are required for diauxic-shift reprogramming and cell survival in stationary phase. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 7012-7017.	7.1	45
27	The causative role and therapeutic potential of the kynurenine pathway in neurodegenerative disease. Journal of Molecular Medicine, 2013, 91, 705-713.	3.9	42
28	Mitochondrial SIRT3 confers neuroprotection in Huntington's disease by regulation of oxidative challenges and mitochondrial dynamics. Free Radical Biology and Medicine, 2021, 163, 163-179.	2.9	42
29	Copy-number variation of the neuronal glucose transporter gene SLC2A3 and age of onset in Huntington's disease. Human Molecular Genetics, 2014, 23, 3129-3137.	2.9	38
30	A brain-permeable inhibitor of the neurodegenerative disease target kynurenine 3-monooxygenase prevents accumulation of neurotoxic metabolites. Communications Biology, 2019, 2, 271.	4.4	36
31	Connecting the dots in Huntington's disease with protein interaction networks. Genome Biology, 2005, 6, 210.	9.6	35
32	Drosophila eye color mutants as therapeutic tools for Huntington disease. Fly, 2012, 6, 117-120.	1.7	34
33	The Parkinsonâ€™s Disease-Linked Protein DJ-1 Associates with Cytoplasmic mRNP Granules During Stress and Neurodegeneration. Molecular Neurobiology, 2019, 56, 61-77.	4.0	33
34	Protein phosphatase 1 regulates huntingtin exon 1 aggregation and toxicity. Human Molecular Genetics, 2017, 26, 3763-3775.	2.9	32
35	Parkinsonâ€™s disease-associated mutations in DJ-1 modulate its dimerization in living cells. Journal of Molecular Medicine, 2013, 91, 599-611.	3.9	31
36	Drosophila Nrf2/Keap1 Mediated Redox Signaling Supports Synaptic Function and Longevity and Impacts on Circadian Activity. Frontiers in Molecular Neuroscience, 2019, 12, 86.	2.9	31

#	Article	IF	Citations
37	Nitric oxide-mediated posttranslational modifications control neurotransmitter release by modulating complexin farnesylation and enhancing its clamping ability. PLoS Biology, 2018, 16, e2003611.	5.6	28
38	Glycation potentiates neurodegeneration in models of Huntingtonâ€™s disease. Scientific Reports, 2016, 6, 36798.	3.3	27
39	Modeling Huntington disease in yeast: Perspectives and future directions. Prion, 2011, 5, 269-276.	1.8	27
40	Inflammation control and improvement of cognitive function in COVID-19 infections: is there a role for kynurenine 3-monooxygenase inhibition?. Drug Discovery Today, 2021, 26, 1473-1481.	6.4	20
41	Kynurenine pathway metabolites in cerebrospinal fluid and blood as potential biomarkers in Huntington's disease. Journal of Neurochemistry, 2021, 158, 539-553.	3.9	18
42	Choosing and using Drosophila models to characterize modifiers of Huntington's disease. Biochemical Society Transactions, 2012, 40, 739-745.	3.4	17
43	Connectivity mapping uncovers small molecules that modulate neurodegeneration in Huntingtonâ€™s disease models. Journal of Molecular Medicine, 2016, 94, 235-245.	3.9	14
44	Ablation of kynurenine 3-monooxygenase rescues plasma inflammatory cytokine levels in the R6/2 mouse model of Huntingtonâ€™s disease. Scientific Reports, 2021, 11, 5484.	3.3	14
45	Rab11 as a modulator of synaptic transmission. Communicative and Integrative Biology, 2013, 6, e26807.	1.4	13
46	Advantages of brain penetrating inhibitors of kynurenine-3-monooxygenase for treatment of neurodegenerative diseases. Archives of Biochemistry and Biophysics, 2021, 697, 108702.	3.0	12
47	Dysfunction of <scp>RAB39Bâ€</scp>Mediated Vesicular Trafficking in Lewy Body Diseases. Movement Disorders, 2021, 36, 1744-1758.	3.9	12
48	Maternal genotype determines kynurenic acid levels in the fetal brain: Implications for the pathophysiology of schizophrenia. Journal of Psychopharmacology, 2018, 32, 1223-1232.	4.0	11
49	RAB39B is redistributed in dementia with Lewy bodies and is sequestered within aÎ² plaques and Lewy bodies. Brain Pathology, 2021, 31, 120-132.	4.1	11
50	A novel role for kynurenine 3-monooxygenase in mitochondrial dynamics. PLoS Genetics, 2020, 16, e1009129.	3.5	11
51	Tubulin and Tubulin Posttranslational Modifications in Alzheimerâ€™s Disease and Vascular Dementia. Frontiers in Aging Neuroscience, 2021, 13, 730107.	3.4	9
52	Therapeutic Targeting of Rab GTPases: Relevance for Alzheimerâ€™s Disease. Biomedicines, 2022, 10, 1141.	3.2	9
53	A flexible polyglutamine hinge opens new doors for understanding huntingtin function. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 14516-14517.	7.1	8
54	Assessing and Modulating Kynurenine Pathway Dynamics in Huntingtonâ€™s Disease: Focus on Kynurenine 3-Monooxygenase. Methods in Molecular Biology, 2018, 1780, 397-413.	0.9	8

#	Article	IF	Citations
55	Rab8 Promotes Mutant HTT Aggregation, Reduces Neurodegeneration, and Ameliorates Behavioural Alterations in a Drosophila Model of Huntingtonâ€™s Disease. Journal of Huntington's Disease, 2020, 9, 253-263.	1.9	8
56	Cellular Localization of Kynurenine 3-Monooxygenase in the Brain: Challenging the Dogma. Antioxidants, 2022, 11, 315.	5.1	7
57	A Novel Sit4 Phosphatase Complex Is Involved in the Response to Ceramide Stress in Yeast. Oxidative Medicine and Cellular Longevity, 2013, 2013, 1-9.	4.0	6
58	Aggregation-Prone Proteins Modulate Huntingtin Inclusion Body Formation in Yeast. PLOS Currents, 2014, 6, .	1.4	5
59	Understanding neuronal dysfunction and loss in neurodegenerative disease. Journal of Molecular Medicine, 2013, 91, 651-652.	3.9	4
60	Synapses and Î±-synuclein signalling in disease. Cogent Biology, 2015, 1, 1085295.	1.7	2
61	Esculetin Provides Neuroprotection against Mutant Huntingtin-Induced Toxicity in Huntingtonâ€™s Disease Models. Pharmaceuticals, 2021, 14, 1044.	3.8	2
62	Is modulating translation a therapeutic option for Huntingtonâ€™s disease?. Neurodegenerative Disease Management, 2011, 1, 89-91.	2.2	1
63	Î²-Defensin Genomic Copy Number Does Not Influence the Age of Onset in Huntington's Disease. Journal of Huntington's Disease, 2013, 2, 107-124.	1.9	1
64	Modeling Huntington Disease in Yeast and Invertebrates. , 2015, , 557-572.		0